Elutia Inc.
Elutia Inc. (Nasdaq: ELUT) develops and sells biologic matrix products for surgical reconstruction and repair, and is advancing drug-eluting biomatrix programs intended to address complications such as infection and inflammation. Its commercial portfolio includes SimpliDerm, a human acellular dermal matrix used in… From the company’s description.
Over the twelve months to Jun 30, 2026, Elutia Inc. reported revenue of $5.54M and net income of $51.81M. Its operating margin was −422.6%, and operations used $43.99M in cash. In fiscal 2025, it reported revenue of $12.29M and net income of $53.38M.
Dotted labels explain each measure. is shown separately from the annual figures.
What Elutia Inc. does
In the company’s own words
Elutia Inc. (Nasdaq: ELUT) develops and sells biologic matrix products for surgical reconstruction and repair, and is advancing drug-eluting biomatrix programs intended to address complications such as infection and inflammation. Its commercial portfolio includes SimpliDerm, a human acellular dermal matrix used in soft-tissue reconstruction, and cardiovascular repair products ProxiCor, Tyke and VasCure, made from porcine small-intestinal tissue. Customers include plastic and reconstructive surgeons, cardiovascular and vascular surgeons, hospitals and other healthcare facilities; products are sold through independent sales agents. Elutia reports Women’s Health and Cardiovascular as its current commercial segments, with SimpliDerm the primary Women’s Health product and the repair products in Cardiovascular. Its development programs, NXT-41 and antibiotic-eluting NXT-41x, target reconstructive applications. In October 2025, the company sold its cardiac-device protection business, including CanGaroo and EluPro, to Boston Scientific and Cardiac Pacemakers Inc.; it had previously sold its Orthobiologics business in 2023. Its investor relations website is https://investors.Elutia.com/financials/sec-filings.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SILVER SPRING, MD
- Fiscal year end
- December
- CIK
- 1708527
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Elutia Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Elutia Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Elutia Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Elutia Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Elutia Inc.'s last four quarterly filings that the numbers alone won't show?”